P
Precision Biologics
Biotech & Life Sciences · Dallas, United States · Founded 2012
Cancer immunotherapy platform with 2 unique clinical stage monoclonal antibodies MoreLess
Precision Biologics is a pioneering company in the biotherapeutics and diagnostics sector, dedicated to improving the lives of cancer patients through innovative products. The company specializes in developing targeted monoclonal antibodies designed to attack tumors without harming healthy cells. Operating primarily in the oncology market, Precision Biologics serves healthcare providers and research institutions focused on cancer treatment and diagnostics. The business model revolves around the development and clinical trials of its proprietary antibodies, which are then licensed to pharmaceutical companies or sold directly to healthcare providers. Revenue is generated through licensing fees, sales of therapeutic products, and partnerships with other biotech firms. The company is currently advancing its first monoclonal antibody, NEO 102, through Phase 1 and 2 clinical trials for pancreatic and colorectal cancer.
Keywords: biotherapeutics, diagnostics, monoclonal antibodies, cancer treatment, oncology, clinical trials, NEO 102, targeted therapy, healthcare providers, biotechnology.
Company overview
Precision Biologics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Dallas, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 26.3
Valuation & funding
Precision Biologics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Oct 2015 | $50M | $200M | NantCell | Nantworks | — |
| EARLY VCOther financing | Apr 2014 | $800K | $3.2M | Undisclosed | — |
| EARLY VCOther financing | May 2013 | $3.3M | $13M | Undisclosed | — |
| SEEDOther financing | Oct 2012 | $5.3M | $21M | Undisclosed | — |
| SPINOUTOther financing | Feb 2012 | $0 | — | The George Washington University | — |
Growth signals
Precision Biologics website traffic
Latest recorded traffic for Precision Biologics is 1.2K monthly website visits, up 0% over the last three months. Precision Biologics's team grew 0% over the past year.
Comparisons
Precision Biologics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Precision Biologics's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Precision Biologics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Precision Biologics has talent and traffic
team presence
In the news
Latest news about Precision Biologics
Recent press, funding announcements, and product moves mentioning Precision Biologics — open to read from the original sources.
Market sentiment
What the market is saying about Precision Biologics
An AI-synthesized read of the highest-engagement posts about Precision Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Precision Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.